Business Wire

NY-PHILIP-MORRIS-INTL

14.9.2020 10:01:12 CEST | Business Wire | Press release

Share
Public Wants Greater Focus on Science-Based Decision-Making Says New International Survey from Philip Morris International

Philip Morris International Inc. (PMI) (NYSE: PM) today released “In Support of the Primacy of Science ,” a white paper exploring international attitudes regarding the role of science in society, business, and policymaking. The white paper—presenting findings from an independent survey, conducted by Povaddo for PMI, of over 19,000 adults across 19 countries and territories—indicates that citizens around the world want governments, public authorities, and private businesses to prioritize science and facts when tackling critical issues.

The global insights reveal that faith in science is high, with most people surveyed (77 percent) hopeful that advances in science will solve many of society’s biggest problems. Supporting this view, there is also strong interest in businesses prioritizing science, with 90 percent of respondents saying it is important to them that businesses invest continually in science to improve their products.

Despite these positive attitudes, nearly half of respondents (47 percent) believe that society does not place enough importance on science. Given the diverging opinions, the white paper challenges the need for regulators to place greater focus on science to inform policy decisions, with half (51 percent) of respondents believing that their “government does a good job ensuring science and evidence are included in the decision-making process.”

“Science can help make significant strides in our collective efforts to address the world’s most pressing problems” said Dr. Moira Gilchrist, vice president for Strategic & Scientific Communications at PMI. “Unfortunately, governments and broader society have yet to embrace science at its fullest potential, as this global survey shows. Ensuring facts and evidence are given greater prominence in policymaking—over ideology, politics, and unsubstantiated beliefs—will help match the public’s expectations for science to sit at the heart of decisions impacting them and their future.”

The survey also reveals that people’s access to accurate scientific information is far from assured today, with nearly half of the total sample indicating that they find it difficult to access reliable information about scientific developments and relevant studies.

“This finding is alarming and sends a clear signal across business, media, and government that accurately communicating scientific information should remain an important priority,” added Dr. Gilchrist. “When reliable scientific information is in short supply, misinformation, wild guesses, and hearsay can take more space and significantly hamper people’s ability to make informed decisions.”

PMI is undergoing a fundamental transformation into a science- and technology-led company with the aim of delivering a smoke-free future—a future without cigarettes. With the right regulatory encouragement and support from civil society, we believe this goal can be achieved in many countries in 10 to 15 years. Science is central to delivering on this commitment. Since 2008, PMI has invested billions of dollars in developing, testing, and manufacturing better alternatives to cigarettes for adults who would otherwise continue to smoke. These products are the result of nearly two decades of R&D work, underpinned by a rigorous scientific assessment program and led by a team that today includes more than 430 world-class scientists and other experts. We make our scientific findings and methods available for others to scrutinize, we invite independent research into our products, and we encourage a broad, science-based conversation with regulators, scientists, and the public health community about these better alternatives and the role they can play in tobacco control and harm reduction.

To read the “In Support of the Primacy of Science” paper, visit https://www.pmi.com/primacyofscience .

Survey Methodology

Povaddo conducted this online survey on behalf of PMI between June 25 and July 8, 2020. The survey was fielded among 19,100 general population adults ages 21 and older in 19 countries and territories: Argentina, Australia, Brazil, Germany, Hong Kong, Israel, Italy, Japan, Mexico, the Netherlands, Norway, the Philippines, Russia, South Africa, South Korea, Taiwan, the United Kingdom, the United States, and Vietnam. For the overall sample, there is a margin of error of +/- 0.72% at the 95% confidence interval.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. PMI ships a version of its smoke-free devices and consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the United States under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. For more information, please visit www.pmi.com and www.pmiscience.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release

Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm

Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release

- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno

The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release

New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights

Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 08:00:00 CEST | Press release

From dating apps to financial details, respondents report seeing a wide range of highly personal information on others' screens 56% of people admit to having looked at strangers’ phone screens accidentally, whereas 24% have done so out of curiosity. 57% identify public transport as the most likely place to notice someone else's screen. While 48%* feel confident they can keep their phone activity private when using it in crowded places, another 52%** acknowledge it is easy to see someone’s screen who is next to you in a public place without trying to look. 33% say they have seen personal content on a stranger’s phone in public. Some smartphone users who have looked at a stranger’s phone screen in public ignore and continue what they were doing (28%) or look away immediately (27%), but others (7%) admit to continuing to look discreetly. The new Samsung Galaxy S26 Privacy Display1 limits side-angle viewing of your screen to protect your privacy in any setting. As millions of Europeans2 ge

RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release

A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye